We have updated two of our Treatment Selectors: the Antiepileptic Treatment Selector and the Recreational Drugs Treatment Selector. These give overviews of interactions with DAAs within the corresponding indication.
The Antiepileptic Treatment Selector has been updated to reflect new data and experience of coprescribing enzyme-inducing antiepileptics and DAAs. Several published case series indicate that it can be possible to achieve SVR when coadministering certain DAAs and enzyme-inducing antiepileptics, where therapeutic drug monitoring is possible. These combinations should be avoided if at all possible, but these new recommendations mean patients can be treated when the combination cannot be avoided. The website and app have both been updated with these new recommendations.
The Recreational Drugs Treatment Selector has been updated with fentanyl as a recreational drug instead of a prescribed drug. The interaction for recreational use has been downgraded from AMBER to YELLOW. This is due to the extreme variability in fentanyl as ingested as a recreational drug, which is more likely to drive adverse effects than the interaction with glecaprevir/pibrentasvir, which is a weak inhibitor. However, users still need to be aware of the potential for increased side effects, such as sedation and respiratory depression.
